Final Benefits & Payment Rule a “Win for Patients”

WASHINGTON, D.C. (April 28, 2022) – The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the following statement after the Centers for Medicare & Medicaid Services finalized the Notice of Benefit and Payment Parameters (NBPP) rule that includes policies to help lower out-of-pocket costs for patients:

“Today’s Biden Administration decision on standardized benefit designs is a win for patients by ensuring insurance works like it should. This will make a real difference in lowering costs at the pharmacy for patients who get their insurance from HealthCare.gov. These types of reforms help build a better health care system for everyone.”

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $800 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.MAT.org
www.Facebook.com/PhRMA
www.X.com/PhRMA